Lancashire and South Cumbria
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-01-01 Sodium oxybate
Sodium Oxybate
Formulary
Oral solution 500mg/mL
For narcolespsy with cataplexy under expert supervision
Links
LSCMMG: Melatonin
LSCMMG: Melatonin
LSCMMG: Melatonin Pathway (Children)
MHRA Drug Safety Update March 2020: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
MHRA Drug Safety Update Oct 2021:Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
MHRA: Changes to drug driving law
MHRA: Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
MHRA: Drugs and driving: blood concentration limits to be set for certain controlled drugs in a new legal offence
MHRA: Risk of drowsiness and reduced driving ability
MHRA: Zolpidem: risk of drowsiness and reduced driving ability
NICE Evidence summary: Melatonin for sleep disorders in children with ADHD
NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
NICE TA922: Daridorexant for treating long-term insomnia
NICE TAG 77 : Zaleplon, zolpidem and zopiclone for the management of insomnia
NICE TAG 77 :Zaleplon, zolpidem and zopiclone for the management of insomnia
Key
Full Site